Brief: Apellis Pharmaceuticals Q2 Basic EPS USD -0.33

Apellis Pharmaceuticals

31/07/2025 12:05

Overview

Apellis Q2 revenue falls to $178.5 mln, down from $199.7 mln last year

Company received FDA approval for EMPAVELI for C3G and primary IC-MPGN

Apellis enters $300 mln royalty agreement with Sobi for Aspaveli

Outlook

Apellis expects EMA opinion on Aspaveli indication extension by year-end 2025

Company plans pivotal studies for DGF and FSGS in 2H 2025

Apellis anticipates cash and revenues will fund business to profitability

Result Drivers

FDA APPROVAL - Received U.S. FDA approval for EMPAVELI for C3G and primary IC-MPGN, expected to enhance market position, per CEO Cedric Francois

SYFOVRE DEMAND - SYFOVRE injection demand increased 6% qtr-over-qtr, contributing $151 mln to U.S. net product revenue

ROYALTY AGREEMENT - Entered $300 mln royalty purchase agreement with Sobi for 90% of ex-U.S. royalties of Aspaveli

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
$171.39 mln
Q2 EPS
-$0.33
Q2 Net Income
-$42.15 mln
Q2 Basic EPS
-$0.33
Q2 Operating Expenses
$211.78 mln
Q2 Operating Income
-$33.29 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Apellis Pharmaceuticals Inc is $29.00, about 34.5% above its July 30 closing price of $19.00

Press Release: ID:nGNX3cKpSf

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)